Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
REGENXBIO
ISIN US75901B1070
|WKN A140E0
Marktkapitalisatie (in EUR)
387 m
Land
United States
Sector
Healthcare
Dividendrendement
0.00%
Overzicht
Beschrijving
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financiële kerngegevens
Kerncijfers
| Marktkapitalisatie, EUR | 387 m |
| WPA, EUR | -3.33 |
| KBV | 4.3 |
| K/W | - |
| Dividendrendement | 0.00% |
Income statement (2025)
| Omzet, EUR | 151 m |
| Netto-inkomen, EUR | -172 m |
| Winstmarge | -113.75% |
What ETF is REGENXBIO in?
There is 1 ETF which contains REGENXBIO.
| ETF | Weging | Investeringsfocus | Fondsgrootte (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.05% | Equity United States Health Care Biotech | 48 |
Nieuwste artikelen
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.
Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.